» Articles » PMID: 20713524

MiR-335 Directly Targets Rb1 (pRb/p105) in a Proximal Connection to P53-dependent Stress Response

Overview
Journal Cancer Res
Specialty Oncology
Date 2010 Aug 18
PMID 20713524
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Loss-of-function mutations of retinoblastoma family (Rb) proteins drive tumorigenesis by overcoming barriers to cellular proliferation. Consequently, factors modulating Rb function are of great clinical import. Here, we show that miR-335 is differentially expressed in human cancer cells and that it tightly regulates the expression of Rb1 (pRb/p105) by specifically targeting a conserved sequence motif in its 3' untranslated region. We found that by altering Rb1 (pRb/p105) levels, miR-335 activates the p53 tumor suppressor pathway to limit cell proliferation and neoplastic cell transformation. DNA damage elicited an increase in miR-335 expression in a p53-dependent manner. miR-335 and p53 cooperated in a positive feedback loop to drive cell cycle arrest. Together, these results indicate that miR-335 helps control proliferation by balancing the activities of the Rb and p53 tumor suppressor pathways. Further, they establish that miR-335 activation plays an important role in the induction of p53-dependent cell cycle arrest after DNA damage.

Citing Articles

The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications.

Mirandari A, Parker H, Ashton-Key M, Stevens B, Walewska R, Stamatopoulos K Explor Target Antitumor Ther. 2024; 5(4):877-901.

PMID: 39280243 PMC: 11390296. DOI: 10.37349/etat.2024.00253.


Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells-A....

Mizielska A, Dziechciowska I, Szczepanski R, Cisek M, Dabrowska M, Slezak J Genes (Basel). 2023; 14(3).

PMID: 36980974 PMC: 10048428. DOI: 10.3390/genes14030702.


The Potential of Senescence as a Target for Developing Anticancer Therapy.

Jo H, Shim K, Jeoung D Int J Mol Sci. 2023; 24(4).

PMID: 36834846 PMC: 9961771. DOI: 10.3390/ijms24043436.


Exosomal delivery of TRAIL and miR‑335 for the treatment of hepatocellular carcinoma (Review).

Thapa N, Chwae Y, Yoo K, Won T, Kang D, Choi D Int J Mol Med. 2022; 51(1).

PMID: 36416311 PMC: 9728509. DOI: 10.3892/ijmm.2022.5206.


MicroRNAs and the Diagnosis of Childhood Acute Lymphoblastic Leukemia: Systematic Review, Meta-Analysis and Re-Analysis with Novel Small RNA-Seq Tools.

Kyriakidis I, Kyriakidis K, Tsezou A Cancers (Basel). 2022; 14(16).

PMID: 36010971 PMC: 9406077. DOI: 10.3390/cancers14163976.